Navigation Links
New Data Shows Significant Asthma Control With Symbicort

New data showed that using SYMBICORT? for asthma provides a rapid and clinically significant bronchodilatory response and improvement// in lung function within 15 minutes after administration.

In addition, these data demonstrated that in comparison to its monocomponents (budesonide and formoterol) and placebo, SYMBICORT and the other treatment groups containing formoterol had a faster bronchodilatory response than budesonide or placebo. The combined study results, involving patients with mild-to-severe persistent asthma who previously required treatment with inhaled corticosteroids (ICS), were presented at the annual meeting of the American Academy of Allergy, held in San Diego.

SYMBICORT is a newly approved, twice-daily, inhaled combination therapy containing budesonide, a corticosteroid, and formoterol, a rapid and long-acting beta2-agonist. It is indicated for the long-term maintenance treatment of asthma in patients ages 12 and older. SYMBICORT is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled, short-acting beta2-agonists.

Additional data from these studies presented at AAAAI showed SYMBICORT provided significantly greater improvements in asthma control compared to its monocomponents (budesonide or formoterol) or placebo in patients with mild-to-moderate asthma who required an ICS. In patients with moderate-to-severe asthma who required an ICS, SYMBICORT also demonstrated significantly greater improvement in lung function compared to its monocomponents (budesonide or formoterol) or placebo.

'With an estimated 20 million patients currently suffering from asthma in the U.S., SYMBICORT represents an exciting new treatment option and a welcome addition to our respiratory franchise,' said Chris O'Brien, Senior Director, Medical Science, AstraZeneca. 'We are dedicated to the development of new, effective treatments to improve lung healt h and are looking forward to making SYMBICORT available in the U.S.'

Source-Eurekalert
'"/>




Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. AIDS drug GS 9137 Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: